Alexander Weissensee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexander Weissensee has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Klaus Strobel
Department of Nuclear Medicine and Radiology, Cantonal Hospital Lucerne, University Teaching and Research Hospital, University of Lucerne, Luzern, Switzerland
2 shared publicationsAlan Daniel Sidandy
Inselspital University Hospital Bern, Switzerland
1 shared publicationAli Afshar-Oromieh
Inselspital University Hospital Bern, Switzerland
1 shared publicationAndrea Zander
Department of Nuclear Medicine and Radiology, Cantonal Hospital Lucerne, University Teaching and Research Hospital, University of Lucerne, Luzern, Switzerland
1 shared publicationAxel Rominger
Inselspital University Hospital Bern, Switzerland
1 shared publication- Axel Rominger
Department of Nuclear Medicine, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland
1 shared publication
Latest Publications
- 12 November 2026
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
Pharmacokinetics of Prostate Cancer Lesions on Dual Time-Point PET/CT: A Predictive Factor for Response to PSMA Radioligand Therapy?
Prostate cancer (PC) lesions usually show increasing uptake of prostate-specific membrane antigen (PSMA) ligands over time. We investigated whether the intensity changes of PSMA-ligand uptake on dual-time-point positron emission tomography/computed tomography (PET/CT) can predict the response to [177Lu]Lu-PSMA radioligand therapy (PSMA-RLT). Nineteen patients who underwent dual-time-point [18F]PSMA-1007 PET/CT before PSMA-RLT were retrospectively analysed. Standardised uptake values were measured for local prostate cancer lesions and lymph node, bone, and organ metastases. These groups were compared for maximum standardised uptake value (SUVmax) differences between standard and late scans. Using Firth’s bias-reduced logistic regression, we assessed whether change in SUVmax between standard and late scans (ΔSUVmax) correlates with long-term biochemical response to PSMA-RLT. We analysed 355 PC lesions (14 local tumours, 171 bone, 132 lymph node, and 38 organ metastases). Across all lesions, the median SUVmax in late scans was 15.2% higher than that in standard scans (p<0.001). A mixed-effects model accounting for clustering within patients suggested differences in relative ΔSUVmax across metastasis types, although these did not reach statistical significance (p=0.058). Logistic regression showed no correlation of ΔSUVmax to therapy response likelihood (odds ratio=1.01, p=0.85). In contrast, the SUVmax of the hottest measured lesion significantly predicted the therapy response (odds ratio=1.11 per unit increase, 95% confidence interval: 1.02–1.26, p=0.005). PC lesions exhibited significantly higher PSMA-ligand uptake in late scans. However, the magnitude of this increase neither differed significantly across PC lesion types nor correlated with response to PSMA-RLT. Notably, higher SUVmax during standard time-point imaging were associated with an increased likelihood of biochemical response to PSMA-RLT.
- 12 November 2026
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
Pharmacokinetics of Prostate Cancer Lesions on Dual Time-Point PET/CT: A Predictive Factor for Response to PSMA Radioligand Therapy?
Prostate cancer (PC) lesions usually show increasing uptake of prostate-specific membrane antigen (PSMA) ligands over time. We investigated whether the intensity changes of PSMA-ligand uptake on dual-time-point positron emission tomography/computed tomography (PET/CT) can predict the response to [177Lu]Lu-PSMA radioligand therapy (PSMA-RLT). Nineteen patients who underwent dual-time-point [18F]PSMA-1007 PET/CT before PSMA-RLT were retrospectively analysed. Standardised uptake values were measured for local prostate cancer lesions and lymph node, bone, and organ metastases. These groups were compared for maximum standardised uptake value (SUVmax) differences between standard and late scans. Using Firth’s bias-reduced logistic regression, we assessed whether change in SUVmax between standard and late scans (ΔSUVmax) correlates with long-term biochemical response to PSMA-RLT. We analysed 355 PC lesions (14 local tumours, 171 bone, 132 lymph node, and 38 organ metastases). Across all lesions, the median SUVmax in late scans was 15.2% higher than that in standard scans (p<0.001). A mixed-effects model accounting for clustering within patients suggested differences in relative ΔSUVmax across metastasis types, although these did not reach statistical significance (p=0.058). Logistic regression showed no correlation of ΔSUVmax to therapy response likelihood (odds ratio=1.01, p=0.85). In contrast, the SUVmax of the hottest measured lesion significantly predicted the therapy response (odds ratio=1.11 per unit increase, 95% confidence interval: 1.02–1.26, p=0.005). PC lesions exhibited significantly higher PSMA-ligand uptake in late scans. However, the magnitude of this increase neither differed significantly across PC lesion types nor correlated with response to PSMA-RLT. Notably, higher SUVmax during standard time-point imaging were associated with an increased likelihood of biochemical response to PSMA-RLT.
- Open Access
- 5 August 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (13) , 7680-7682
Occult metastases detection and impact on management in renal cell carcinoma imaged with [89Zr]Zr-girentuximab
- 5 August 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (13) , 7680-7682
Open AccessOccult metastases detection and impact on management in renal cell carcinoma imaged with [89Zr]Zr-girentuximab
- Open Access
- 6 April 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (10) , 1-2
Coronary periarteritis as a rare cause of angina in a runner: hybrid PET/CT findings
- 6 April 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (10) , 1-2
Open AccessCoronary periarteritis as a rare cause of angina in a runner: hybrid PET/CT findings
- Open Access
- 26 December 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (4) , 300-308
Imaging of Small Lung Nodules on Modern SAFOV and LAFOV PET in Combination With Data-driven Motion Correction: Implications for Current Practice
Purpose: Guidelines recommend [ 18 F]FDG PET/CT for lung nodules >8 mm only. For smaller lesions, PET/CT has not been recommended due to lower lesion conspicuity. However, this threshold was established using earlier generations of PET scanners. In this work, we sought to evaluate the combined effects of modern scanner technology, long-axial-field-of-view (LAFOV) PET and data-driven respiratory motion correction on lung nodule imaging. Materials and Methods: We identified 55 consecutive patients with lung nodules who underwent [ 18 F]FDG PET/CT for a known or suspected malignancy. We created image reconstructions with combinations of simulated short-axial-field-of-view (sSAFOV), LAFOV, and data-driven gating (DDG) and measured effects on image parameters. We then gathered follow-up data (over 13 mo) to establish nodule benignity or malignancy and evaluated effects on diagnostic accuracy with receiver-operating-characteristic (ROC) analysis. Results: All methods showed good to excellent diagnostic accuracy, even for nodules max by 32%. The combination of LAFOV and DDG showed the highest image quality improvement compared with sSAFOV, with a median improvement in contrast-to-noise ratio (CNR) of 29%. Conclusions: Data-driven motion correction and LAFOV-PET provide synergistic improvements in image quality. Furthermore, the high diagnostic accuracy of sSAFOV reconstructions for lung nodules ≤8 mm, and even <6 mm, indicates that assessment of lung nodules smaller than current guideline recommendations might be possible.
- 26 December 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (4) , 300-308
Open AccessImaging of Small Lung Nodules on Modern SAFOV and LAFOV PET in Combination With Data-driven Motion Correction: Implications for Current Practice
Purpose: Guidelines recommend [ 18 F]FDG PET/CT for lung nodules >8 mm only. For smaller lesions, PET/CT has not been recommended due to lower lesion conspicuity. However, this threshold was established using earlier generations of PET scanners. In this work, we sought to evaluate the combined effects of modern scanner technology, long-axial-field-of-view (LAFOV) PET and data-driven respiratory motion correction on lung nodule imaging. Materials and Methods: We identified 55 consecutive patients with lung nodules who underwent [ 18 F]FDG PET/CT for a known or suspected malignancy. We created image reconstructions with combinations of simulated short-axial-field-of-view (sSAFOV), LAFOV, and data-driven gating (DDG) and measured effects on image parameters. We then gathered follow-up data (over 13 mo) to establish nodule benignity or malignancy and evaluated effects on diagnostic accuracy with receiver-operating-characteristic (ROC) analysis. Results: All methods showed good to excellent diagnostic accuracy, even for nodules max by 32%. The combination of LAFOV and DDG showed the highest image quality improvement compared with sSAFOV, with a median improvement in contrast-to-noise ratio (CNR) of 29%. Conclusions: Data-driven motion correction and LAFOV-PET provide synergistic improvements in image quality. Furthermore, the high diagnostic accuracy of sSAFOV reconstructions for lung nodules ≤8 mm, and even <6 mm, indicates that assessment of lung nodules smaller than current guideline recommendations might be possible.